Preliminary data from phase II the GALAHAD study showed that approximately 40 percent of patients with DRD in BRCA1/2 receiving treatment with niraparib (300 mg daily) demonstrated an objective response, defined by the Response Evaluation Criteria in Solid Tumors guideline, version 1.1, as a standard measure of tumor response.
Cancer researchers have long known that prostate cancer tends to be more common, more aggressive and more resistant to existing treatments in African Americans than in Caucasian Americans, but they're only beginning to understand why.
AVEO Oncology announced the presentation of data from the phase III TIVO-3 study of tivozanib (Fotivda) versus sorafenib in refractory advanced or metastatic renal cell carcinoma.
Researchers at MD Anderson Cancer Center have discovered that a combination of immune checkpoint blockade and targeted therapies that block normal DNA damage repair achieved significant tumor regression in mouse models of small cell lung cancer, suggesting a promising new approach for treating patients with this aggressive cancer.
Melanoma tumors that have spread to the brain are equipped to thwart immunotherapies and targeted therapies that succeed against tumors growing in other sites. Researchers at MD Anderson Cancer Center report in Cancer Discovery that the heavy reliance of these tumors on a specific metabolic pathway presents a potentially new therapeutic against these lethal tumors.
A new study has identified a drug that potentially could make a common type of immunotherapy for cancer even more effective. The study in laboratory mice found that the drug dasatinib, which is FDA-approved to treat certain types of leukemia, greatly enhances responses to a form of immunotherapy that is used against a wide range of other cancers.
New research in the February 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network calls for greater integration between cardiologists and oncologists for patients with coronary artery disease who are diagnosed with cancer.
The first clinical study investigating the use of the direct oral anticoagulant, rivaroxaban, to prevent blood clots in patients with cancer at high-risk has been published in the New England Journal of Medicine.
Merck announced new combination and monotherapy data from the company's immuno-oncology research program in genitourinary cancers will be presented at the 2019 Genitourinary Cancers Symposium in San Francisco Feb. 14-16.
The first study of the immunotherapy drug pembrolizumab as the initial treatment for patients with Merkel cell carcinoma reports better responses and longer survival than expected with conventional chemotherapy, the researchers said.
